ClinicalTrials.gg
RecruitingNCT06134908PROTECT-2Updated May 28, 2024

PRevention of OsTEoporotiC FracTure 2 Pilot Study

An interventional study of Multifaceted Intervention in Fragility Fracture, sponsored by Third Affiliated Hospital, Sun Yat-Sen University. Recruiting at 7 sites in China. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2024-05-28.

Sponsored by Third Affiliated Hospital, Sun Yat-Sen University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2025, 1 year 5 months ago, but the record still lists the study as recruiting.
  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
48th of 57
50 · median 120
Started
2024
with 9 others
No phase
19 of 87
5 open now
Primary completion
2025-06
later than 6 of 32 live
Registered
56th of 87
by date

Among the 87 studies in Osteoporosis with a site in China, this one is the 48th largest by planned enrollment of the 57 interventional ones that give a count, is one of 10 that started in 2024, is one of 19 with no phase, reaches primary completion later than 6 of the 32 other live ones, and was the 56th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 209 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

With the aging of the world population, osteoporosis and fragility fractures have become global public health concerns. It has been estimated the population of people ≥60 years of age will increase from 229 million (16.2%) in 2017 to 479 million (35.1%) by 2050 in China. Because age is an important predictor of osteoporosis and fragility fracture, the incidence of fragility fracture has increased dramatically in China over the past decades. Timely treatment of osteoporosis is an effective way to decrease additional fracture risk among patients with fragility fractures, but anti-osteoporosis treatment rate is relatively low in China. Effective fracture prevention intervention is urgently needed in China.

As a potential way to achieve effective risk communication, shared decision-making allows patients to be active participants in the management of osteoporosis. The investigators designed a multifaceted intervention, which was named as "Precise Education + Shared Decision-Making" program for the secondary prevention of fragility fractures based on behavioral theories, and assessed the effectiveness for fracture prevention using a pilot cluster randomized controlled trial among several hospitals in China.

The aim of this pilot study is to test the acceptability and feasibility as well as preliminary efficacy of this program in patients with fragility fractures.

03

Conditions studied

  • Fragility Fracture

Browse trials for

Keywords

  • Osteoporosis
  • Fragility Fracture
  • Shared Decision-Making
  • Education
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Local residents (live in the city where the hospital is located for half a year or more);
  2. Hospitalized patients with fractures aged 50 years and above;
  3. First fracture, without history of fracture;
  4. Never diagnosed as "osteoporosis" before admission;
  5. No fracture history, and never receive any bone mineral density test, and never take anti-osteoporosis medication in the 4 years before admission;
  6. Hospitalized patients with the following fractures: hip fracture, thoracic spine fracture, and lumbar spine fracture;
  7. New fragility fracture: fracture that occurs after minor trauma or daily activities, such as a fracture caused by a fall from standing height or less; fracture happened within 6 weeks;
  8. Not living in a nursing or rehabilitation institution before fracture;
  9. Possess reading ability, and can read and understand forms or medical materials independently.

Exclusion criteria

Exclusion Criteria:

  1. Patients with pathological fractures caused by tumor or infection;
  2. Patients with cognitive dysfunction or mental disorder;
  3. AIDS patients;
  4. Patients who refuse to follow-up, or have poor compliance for follow-up, or fail to understand and cooperate for follow-up;
  5. Hearing or visual impairment, and unable to communicate or read materials;
  6. Patients who have participate in other studies;
  7. Other conditions that the investigator considered inappropriate to enroll.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Multifaceted Intervention

    Group in the intervention arm will receive a multicomponent intervention at the clinician- and patient-level, with a shared decision-making booklet as well as a mobile application to promote osteoporosis management and fracture practice.

    Behavioral: Multifaceted Intervention

  • No intervention
    Usual-care Control

    Group in the control arm will receive a leaflet and routine medical care per their existing health care providers.

Interventions

  • BehavioralMultifaceted Intervention

    The multicomponent intervention elements include education for clinicians and patients as well as a shared decision-making program among clinicians and patients. A shared decision-making booklet and a mobile application will be used to promote osteoporosis management and fracture practice.

06

What researchers measure

Primary outcomes

  1. Trial feasibility - Recruitment

    Number or N (%) participants recruited within 3 months of trial initiation at each centre.

    Time frame: 3 months

  2. Trial feasibility - Acceptability of the multicomponent program component

    Participants will be asked to evaluate the program with a questionnaire with questions about frequency, length, content, delivery, and duration of the booklet and the mobile application using a 5-point Likert scale.

    Time frame: 30 days after study recruitment

  3. Trial feasibility - Acceptability of the shared decision-making process

    Both clinicians and patients will be asked to evaluate the shared decision-making process once they completed it. A survey will be administered to evaluate the content and comprehension of the program using a 5-point Likert scale.

    Time frame: 7 days after study recruitment

  4. Trial feasibility - Retention

    The retention rates will be assessed as the 30-day follow-up rate.

    Time frame: 30 days after study recruitment

Secondary outcomes

  1. Anti-osteoporosis treatment rate

    The patients will be followed up and asked whether they accept any anti-osteoporosis medication.

    Time frame: 1 month follow-up; 3 month follow-up; 6 month follow-up; 12 month follow-up; 24 month follow-up

  2. Shared decision-making process

    Standardized questionnaires will be used to evaluated the shared decision-making process.

    Time frame: 7 days after study recruitment

  3. Bone mineral density test

    The patients will be followed up and asked whether they accept bone mineral density test.

    Time frame: 3 month follow-up; 6 month follow-up; 12 month follow-up; 24 month follow-up

  4. Adherence of anti-osteoporosis medication

    Adherence of anti-osteoporosis medication will be assessed with medication possession ratio and self-reported question.

    Time frame: 1 month follow-up; 3 month follow-up; 6 month follow-up; 12 month follow-up; 24 month follow-up

  5. Diagnosis, education, and follow-up practice of osteoporosis

    The patients will be followed up with questionnaires about diagnosis, education, and follow-up of osteoporosis.

    Time frame: 1 month follow-up; 3 month follow-up; 6 month follow-up; 12 month follow-up; 24 month follow-up

  6. Refracture

    The patients will be followed up and asked whether they have refracture.

    Time frame: 1 month follow-up; 3 month follow-up; 6 month follow-up; 12 month follow-up; 24 month follow-up

  7. Survival

    The patients will be followed up about their survival status.

    Time frame: 1 month follow-up; 3 month follow-up; 6 month follow-up; 12 month follow-up; 24 month follow-up

  8. Patients' knowledge and attitude about osteoporosis and fragility fracture

    Patients' knowledge and attitude about osteoporosis and fragility fracture will be evaluated with standardized questionnaires.

    Time frame: baseline; 1 month follow-up; 6 month follow-up

07

Study locations

7 of 7 sites recruiting
  • The Second Affiliated Hospital of Hunan University of Chinese Medicine
    Changsha, China
    Recruiting
    • Jingqi Zeng, MD · Contact
  • Dongguan Eighth People's Hospital
    Dongguan, China
    Recruiting
    • Wenbo Cui, MD · Contact
  • Third Affiliated Hospital, Sun Yat-sen University
    Guangzhou, China
    Recruiting
  • Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
    Hangzhou, China
    Recruiting
    • Shunwu Fan, MD · Contact
  • The First People's Hospital of Hefei
    Hefei, China
    Recruiting
    • Zhou Dong, MD · Contact
  • Longgang Orthopedics Hospital of Shenzhen
    Shenzhen, China
    Recruiting
    • Jie Li, MD · Contact
  • The Third People's Hospital of Longgang District Shenzhen
    Shenzhen, China
    Recruiting
    • Shaomin Huang, MD · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Jun 2025, 17 months after the start.

Of 220 non-industry interventional studies with no phase under Osteoporosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 49. This study's planned 17 months is below that.

Counting every sponsor, half of 239 studies reached it within 26 months; a quarter within 9 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 11, 2023
First posted
Nov 18, 2023
StartActual
Jan 13, 2024
Primary completionEst.
Jun 2025
CompletionEst.
Jun 2027
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06134908
Collaborators
Sir Run Run Shaw Hospital, The Second Affiliated Hospital of Hunan University of Chinese Medicine, Longgang Orthopedics Hospital of Shenzhen, The First People's Hospital of Hefei, Dongguan Eighth People's Hospital, The Third People's Hospital of Longgang District Shenzhen
Responsible party
Jian Mo (Principal Investigator, Third Affiliated Hospital, Sun Yat-Sen University) — Principal investigator
First posted
Nov 18, 2023
Start date
Jan 13, 2024
Primary completion
Jun 2025 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 28, 2024

Study contacts

Jian Mo, MD
Contact
mojian3@mail.sysu.edu.cn
+86 (020) 85252900
Jian Mo, MD
principal investigator · Third Affiliated Hospital, Sun Yat-Sen University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion